Ocular Therapeutix, Inc. has grown revenue −1.6% a year over three years and 10% a year over five. Revenue growth, 3-year annual rate: −1.6% (Biotechnology median +17%). Revenue growth, 5-year rate: +10%, growth has slowed since the five-year average. Years of annual history on file: 14, FY2012 to FY2025, as filed.

OCULOcular Therapeutix, Inc.

Healthcare

$7.53-38% 1Y

$7.53

$6.8852 weeks$16.11

Is it growing?

Watch

Growth is fading: revenue shrinking (−8% year on year) and operating margin narrowing (−194.8 points).

2 to watch, 1 without data

Revenue trend−8% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +10% a year.

Margin direction−194.8 points operating

Trailing-twelve-month operating margin, -618.4% now against -423.6% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is OCUL growing?

Ocular Therapeutix, Inc. has grown revenue −1.6% a year over three years and 10% a year over five.

−1.6%

Revenue growth, 3-year annual rate · Biotechnology median +17% · shrinking · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +10%
Revenue growth, 5-year rate · −1.6% over three · growth has slowed since the five-year average
Years of annual history on file: 14
Years of annual history on file · FY2012 to FY2025, as filed

Details›